Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Mouse B7-1 / CD80 Protein,  Fc Tag (MALS verified), 100µg  

Recombinant Mouse B7-1 / CD80 Protein, Fc Tag (MALS verified), 100µg

Recombinant Mouse CD80 /B7-1 Protein, C-Fc Tag (Mouse CD80 Fc Chimera) Val 38 - Lys 245 was produced in human 293 cells (HEK293) Fc Tag (MALS verified)

Synonym: recombinant, mouse, protein CD80, B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7

More details

CD0-M5259-100

Availability: within 7 days

286,00 €

Background
B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­ cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas..

Source
Recombinant Mouse CD80 /B7-1 Protein, Fc Tag (CD0-M5259) is expressed from human 293 cells (HEK293). It contains AA Val 38 - Lys 245 (Accession # Q00609-1).
Predicted N-terminus: Val 38

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 50.3 kDa. The protein migrates as 66-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma"
Sonpavde, Maughan, McGregor et al
Cancer Immunol Immunother (2022)
(2) "Inorganic nanosheets facilitate humoral immunity against medical implant infections by modulating immune co-stimulatory pathways"
Yang, Luo, Shen et al
Nat Commun (2022) 13 (1), 4866
(3) "[Effect of Xijiao Dihuang Combined Prescription on Human Dendritic Cell Function Induced by Lipopolysaccharide]"
Yang, Wu, Wang et al
Zhongguo Shi Yan Xue Ye Xue Za Zhi (2022) 30 (4), 1176-1181
Showing 1-3 of 6047 papers.